Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology, Inc. (NASDAQ: CHRS) is a commercial-stage oncology company whose news flow is centered on its PD-1 inhibitor LOQTORZI (toripalimab-tpzi) and a proprietary immuno-oncology pipeline. Company announcements frequently highlight clinical data, regulatory developments, financial results and strategic updates related to its antibody-based cancer therapies.
News about Coherus Oncology often covers LOQTORZI in nasopharyngeal carcinoma (NPC), including long-term survival data from the JUPITER-02 Phase 3 trial evaluating LOQTORZI plus chemotherapy in recurrent or metastatic NPC. Releases also describe LOQTORZI’s approved indications in the United States and its role as the only FDA-approved and available treatment for recurrent, locally advanced or metastatic NPC across all patient subsets and lines of therapy.
Investors and clinicians following CHRS can expect regular updates on pipeline programs such as CHS-114 and casdozokitug. Coherus reports biomarker and proof-of-mechanism data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, in head and neck squamous cell carcinoma and other solid tumors, as well as clinical and translational findings for casdozokitug, a novel IL-27 antagonist in advanced solid tumors including hepatocellular carcinoma and non-small cell lung cancer.
The company’s news stream also includes quarterly financial results, business updates, participation in major healthcare and oncology conferences, and investor-focused events. These items provide context on revenue trends for LOQTORZI, research and development spending on its immuno-oncology programs, and corporate strategy.
For market participants tracking CHRS, the Coherus Oncology news page on Stock Titan aggregates these press releases and related coverage, offering a centralized view of clinical milestones, regulatory disclosures and financial communications that can influence perceptions of the company’s oncology franchise and pipeline progress.
Coherus BioSciences, Inc. announced a clinical collaboration with the Cancer Research Institute (CRI) to explore a combination of LOQTORZI (toripalimab-tpzi) with ENB-003 for the treatment of ovarian cancer. The iPROC platform study aims to investigate the potential benefits of this innovative combination in drug-resistant cancers. The selection of LOQTORZI and ENB-003 for this study is supported by strong preclinical and clinical data, with a focus on advancing meaningful solutions for patients.
Coherus BioSciences, Inc. (NASDAQ: CHRS) will report its first quarter 2024 financial results on May 9, 2024. The management team will host a conference call and webcast to discuss the results and business update. Investors can access the webcast replay and related materials on the Coherus website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Coherus (CHRS)?
What is the market cap of Coherus (CHRS)?
